Highly active retroviral therapy (HAART) is a very effective treatment for HIV-positive patients. Allelic variants of certain proteins have been associated with successful HAART. The PGX-HIV StripAssay^® identifies variants in genes known to be relevant for effective HAART.

PGX-HIV

• HAART has brought about substantial improvements to HIV-positive patients and has led to a significant reduction in AIDS-related mortality in countries with access to the treatment.
• Allelic variants of the multidrug transporter P-glycoprotein 1 (MDR1), cytochrome P450 isozyme 2D6 (CYP2D6), and the C-C chemokine receptor 5 (CCR5) are known to be associated with the best possible outcome of HAART.
• Identification of relevant genetic variations supports better guidance of HIV therapy.
• The PGX-HIV StripAssay^® identifies genetic variants, which influence the efficacy of HAART, and can help to adjust therapy to individual needs.